B-intervention	0	8	Adjuvant
I-intervention	9	21	capecitabine
I-intervention	21	22	,
I-intervention	23	32	docetaxel
I-intervention	32	33	,
I-intervention	34	50	cyclophosphamide
I-intervention	50	51	,
I-intervention	52	55	and
I-intervention	56	66	epirubicin
O	67	70	for
O	71	76	early
O	77	83	breast
O	84	90	cancer
O	90	91	:
O	92	97	final
O	98	106	analysis
O	107	109	of
O	110	113	the
O	114	124	randomized
O	125	130	FinXX
O	131	136	trial
O	136	137	.

O	138	150	Capecitabine
O	151	153	is
O	154	156	an
O	157	163	active
O	164	169	agent
O	170	172	in
O	173	176	the
O	177	186	treatment
O	187	189	of
O	190	196	breast
O	197	203	cancer
O	203	204	.

O	205	207	It
O	208	210	is
O	211	214	not
O	215	220	known
O	221	228	whether
O	229	240	integration
O	241	243	of
O	244	256	capecitabine
O	257	261	into
O	262	264	an
O	265	273	adjuvant
O	274	281	regimen
O	282	286	that
O	287	295	contains
O	296	297	a
O	298	304	taxane
O	304	305	,
O	306	308	an
O	309	322	anthracycline
O	322	323	,
O	324	327	and
O	328	344	cyclophosphamide
O	345	353	improves
O	354	361	outcome
O	362	364	in
O	365	370	early
O	371	377	breast
O	378	384	cancer
O	384	385	.

B-eligibility	386	391	Women
I-eligibility	392	396	with
I-eligibility	397	405	axillary
I-eligibility	406	410	node
I-eligibility	410	411	-
I-eligibility	411	419	positive
I-eligibility	420	422	or
I-eligibility	423	427	high
I-eligibility	427	428	-
I-eligibility	428	432	risk
I-eligibility	433	437	node
I-eligibility	437	438	-
I-eligibility	438	446	negative
I-eligibility	447	453	breast
I-eligibility	454	460	cancer
O	461	465	were
O	466	474	randomly
O	475	483	assigned
O	484	486	to
O	487	494	receive
O	495	501	either
O	502	507	three
O	508	514	cycles
O	515	517	of
O	518	527	docetaxel
O	528	531	and
O	532	544	capecitabine
O	545	546	(
O	546	548	TX
O	548	549	)
O	550	558	followed
O	559	561	by
O	562	567	three
O	568	574	cycles
O	575	577	of
O	578	594	cyclophosphamide
O	594	595	,
O	596	606	epirubicin
O	606	607	,
O	608	611	and
O	612	624	capecitabine
O	625	626	(
O	626	629	CEX
O	629	630	;
O	631	632	n
O	633	634	=
B-intervention-participants	635	638	753
O	638	639	)
O	640	642	or
O	643	648	three
O	649	655	cycles
O	656	658	of
O	659	668	docetaxel
O	669	670	(
O	670	671	T
O	671	672	)
O	673	681	followed
O	682	684	by
O	685	690	three
O	691	697	cycles
O	698	700	of
O	701	717	cyclophosphamide
O	717	718	,
O	719	729	epirubicin
O	729	730	,
O	731	734	and
O	735	747	fluorouracil
O	748	749	(
B-control	749	752	CEF
O	752	753	;
O	754	755	n
O	756	757	=
B-control-participants	758	761	747
O	761	762	)
O	762	763	.

O	764	767	The
O	768	775	primary
O	776	779	end
O	780	785	point
O	786	789	was
B-outcome-Measure	790	800	recurrence
I-outcome-Measure	800	801	-
I-outcome-Measure	801	805	free
I-outcome-Measure	806	814	survival
I-outcome-Measure	815	816	(
I-outcome-Measure	816	819	RFS
I-outcome-Measure	819	820	)
O	820	821	.

O	822	828	During
O	829	830	a
O	831	837	median
O	838	844	follow
O	844	845	-
O	845	847	up
O	848	852	time
O	853	855	of
O	856	858	59
O	859	865	months
O	865	866	,
O	867	870	214
B-outcome	871	874	RFS
I-outcome	875	881	events
O	882	890	occurred
O	891	892	(
B-outcome	892	897	local
I-outcome	898	900	or
I-outcome	901	908	distant
I-outcome	909	920	recurrences
I-outcome	921	923	or
I-outcome	924	930	deaths
O	930	931	;
O	932	934	TX
O	934	935	/
O	935	938	CEX
O	938	939	,
O	940	941	n
O	942	943	=
B-iv-bin-abs	944	946	96
O	946	947	;
O	948	949	T
O	949	950	/
O	950	953	CEF
O	953	954	,
O	955	956	n
O	957	958	=
B-cv-bin-abs	959	962	118
O	962	963	)
O	963	964	.

B-outcome	965	968	RFS
O	969	972	was
O	973	976	not
O	977	990	significantly
O	991	1000	different
O	1001	1008	between
O	1009	1012	the
O	1013	1019	groups
O	1020	1021	(
O	1021	1027	hazard
O	1028	1033	ratio
O	1034	1035	[
O	1035	1037	HR
O	1037	1038	]
O	1038	1039	,
O	1040	1041	0
O	1041	1042	.
O	1042	1044	79
O	1044	1045	;
O	1046	1048	95
O	1048	1049	%
O	1050	1052	CI
O	1052	1053	,
O	1054	1055	0
O	1055	1056	.
O	1056	1058	60
O	1059	1061	to
O	1062	1063	1
O	1063	1064	.
O	1064	1066	04
O	1066	1067	;
O	1068	1069	P
O	1070	1071	=
O	1072	1073	.
O	1073	1076	087
O	1076	1077	;
B-outcome	1078	1079	5
I-outcome	1079	1080	-
I-outcome	1080	1084	year
I-outcome	1085	1088	RFS
O	1088	1089	,
B-iv-bin-percent	1090	1092	86
I-iv-bin-percent	1092	1093	.
I-iv-bin-percent	1093	1094	6
I-iv-bin-percent	1094	1095	%
O	1096	1099	for
O	1100	1102	TX
O	1102	1103	/
O	1103	1106	CEX
O	1107	1108	v
B-cv-bin-percent	1109	1111	84
I-cv-bin-percent	1111	1112	.
I-cv-bin-percent	1112	1113	1
I-cv-bin-percent	1113	1114	%
O	1115	1118	for
O	1119	1120	T
O	1120	1121	/
O	1121	1124	CEF
O	1124	1125	)
O	1125	1126	.

B-iv-bin-abs	1127	1132	Fifty
I-iv-bin-abs	1132	1133	-
I-iv-bin-abs	1133	1136	six
O	1137	1145	patients
O	1146	1154	assigned
O	1155	1157	to
O	1158	1160	TX
O	1160	1161	/
O	1161	1164	CEX
B-outcome	1165	1169	died
O	1170	1176	during
O	1177	1180	the
O	1181	1187	follow
O	1187	1188	-
O	1188	1190	up
O	1191	1199	compared
O	1200	1204	with
B-cv-bin-abs	1205	1207	75
O	1208	1210	of
O	1211	1219	patients
O	1220	1228	assigned
O	1229	1231	to
O	1232	1233	T
O	1233	1234	/
O	1234	1237	CEF
O	1238	1239	(
O	1239	1241	HR
O	1241	1242	,
O	1243	1244	0
O	1244	1245	.
O	1245	1247	73
O	1247	1248	;
O	1249	1251	95
O	1251	1252	%
O	1253	1255	CI
O	1255	1256	,
O	1257	1258	0
O	1258	1259	.
O	1259	1261	52
O	1262	1264	to
O	1265	1266	1
O	1266	1267	.
O	1267	1269	04
O	1269	1270	;
O	1271	1272	P
O	1273	1274	=
O	1275	1276	.
O	1276	1279	080
O	1279	1280	)
O	1280	1281	.

O	1282	1284	In
O	1285	1296	exploratory
O	1297	1305	analyses
O	1305	1306	,
O	1307	1309	TX
O	1309	1310	/
O	1310	1313	CEX
O	1314	1322	improved
B-outcome	1323	1329	breast
I-outcome	1330	1336	cancer
I-outcome	1336	1337	-
I-outcome	1337	1345	specific
I-outcome	1346	1354	survival
O	1355	1356	(
O	1356	1358	HR
O	1358	1359	,
O	1360	1361	0
O	1361	1362	.
O	1362	1364	64
O	1364	1365	;
O	1366	1368	95
O	1368	1369	%
O	1370	1372	CI
O	1372	1373	,
O	1374	1375	0
O	1375	1376	.
O	1376	1378	44
O	1379	1381	to
O	1382	1383	0
O	1383	1384	.
O	1384	1386	95
O	1386	1387	;
O	1388	1389	P
O	1390	1391	=
O	1392	1393	.
O	1393	1396	027
O	1396	1397	)
O	1398	1401	and
B-outcome	1402	1405	RFS
O	1406	1408	in
O	1409	1414	women
O	1415	1419	with
O	1420	1426	triple
O	1426	1427	-
O	1427	1435	negative
O	1436	1443	disease
O	1444	1447	and
O	1448	1450	in
O	1451	1456	women
O	1457	1460	who
O	1461	1464	had
O	1465	1469	more
O	1470	1474	than
O	1475	1480	three
O	1481	1491	metastatic
O	1492	1500	axillary
O	1501	1506	lymph
O	1507	1512	nodes
O	1513	1515	at
O	1516	1519	the
O	1520	1524	time
O	1525	1527	of
O	1528	1537	diagnosis
O	1537	1538	.

O	1539	1541	We
O	1542	1550	detected
O	1551	1557	little
O	1558	1564	severe
O	1565	1569	late
B-outcome	1570	1578	toxicity
O	1578	1579	.

O	1580	1591	Integration
O	1592	1594	of
O	1595	1607	capecitabine
O	1608	1612	into
O	1613	1614	a
O	1615	1622	regimen
O	1623	1627	that
O	1628	1636	contains
O	1637	1646	docetaxel
O	1646	1647	,
O	1648	1658	epirubicin
O	1658	1659	,
O	1660	1663	and
O	1664	1680	cyclophosphamide
O	1681	1684	did
O	1685	1688	not
O	1689	1696	improve
O	1697	1700	RFS
O	1701	1714	significantly
O	1715	1723	compared
O	1724	1728	with
O	1729	1730	a
O	1731	1738	similar
O	1739	1746	regimen
O	1747	1754	without
O	1755	1767	capecitabine
O	1767	1768	.
